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549 A LONGITUDINAL STUDY TO ASSESS THE FUNCTIONAL
CHANGES CAUSED BY HYALURONIC ACID (HA) INJECTION
(DUROLANE) IN OSTEOARTHRITIS KNEES USING
VIBRATION ANALYSIS AND MAGNETIC RESONANCE
IMAGING
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Purpose: The purpose of this longitudinal study was to assess the
functional changes caused by HA acid injection into the knees of patients
suffering from osteoarthritis (OA). Our hypothesis in this ongoing research
project is that Durolane, a type of synthesized HA, which acts as a viscous
lubricating ﬂuid would improve the mechanical functionality of the joint
and reduce friction between the articulating surfaces of the knee. This
improvement would in turn result in less vibration generated by the knee
during motion.
Methods: 11 patients, diagnosed with severe OA, were recruited from
local rheumatology clinics. Before the injection, each patient was tested
with a vibration analysis device. The patient also underwent a full anatom-
ical MRI scan of the knee. In addition, patients were asked to complete
the WOMAC pain, stiffness and functionality assessment questionnaires.
After the baseline vibration recording and MRI of the involved knee,
patients were injected with 3ml of Durolane. After the injection, the patient
was asked to do some mild exercise, for 10 to 15 minutes and a second
vibration test was performed in the injected knee. The patient was asked
to return for follow-up studies one week, 5 weeks, 9 weeks and 13 weeks
after the injection. At each follow-up appointment the injected knee was
tested again with sound analysis and the patient was asked to ﬁll out
the WOMAC questionnaire. At the ﬁnal appointment, the MRI scan of the
injected knee was repeated.
Analysis: As reported elsewhere, we have developed a vibration based
statistical model of the functionality of the articulating surfaces of the knee
in healthy and OA patients. By projecting vibration data from the patients
injected with HA into this statistical model, we expect to identify trends
of improvement after the injection followed by a gradual worsening of the
knee functionality as time elapses and the injection effects disappear.
Results: To date we have performed baseline and early follow-up
measurements in 4 patients. Eleven patients who will be receiving the
Durolane injection have been recruited. Figure 1 shows the hypothesized
results for 1 patient superimposed upon a vibration test report. We
anticipate that such results will allow an objective assessment of the
effectiveness of therapy in each patient.
Figure 1: Hypothesized trajectory of patient’s knee smoothness before
and after receiving Durolane injection
Conclusions: We are hoping that if we get promising results from our
current research, the technique can be used as a potential tool to assess
the functionality of the joint and for monitoring treatment effectiveness.
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Purpose:Osteoarthritis (OA) of the LS spine tends to present with degen-
erative lumbar disc disease (DDD), chronic lumbar radiculopathy (CLR),
muscle spasm (M-SP) and ﬁbromyalgia (FIBRO). Optimal treatment of
this condition can necessitate multiple medications sequenced for the
best clinical effect.
Methods: Traditional medical training has been to avoid opiates even if
the patient’s pain level is moderate to severe and even if basic activities
of daily living remain signiﬁcantly impaired. This is for reasons not only of
narcotic dependency and constipation but also for sleep fragmentation,
anxiety and depression as well. In these instances the patient may ex-
perience unrelenting pain and have profound disturbances on their sleep
cycle. Not untypically the continuous disturbances in their sleep cycle
can be associated with the appearance of FIBRO. Fibrositic tenderpoint’s
located in the paralumbar and sacroiliac regions will further compound
the low back pain that the patient is experiencing.
More recently there has been described an improvement in both the
quality and duration of sleep associated with the use of long-acting
opiates for chronic low back pain associated with osteoarthritis. These
patients can typically experience FIBRO along with the associated chronic
sleep disturbance of their low back pain. The intensity of this pain
frequently is such that it will not allow sufﬁcient pharmacologic sleep
augmentation to occur. This results in less than desired decrease in
tenderpoint discomfort. Once the appropriately titrated dose of long-acting
opiate has been achieved then typically a formulation such as branded
tizanidine capsules can have a very beneﬁcial effect on the patient’s
sleep. Only then will there occur a reduction in ﬁbrositic tenderpoint
discomfort as well as other associated ﬁbromyalgia related symptoms
such as fatigue, stiffness, headache and depression.
Interestingly, ulterior pain modulation of the lower back occurs with the
diclofenac patch 1.3% (applied to the lower back of the aforementioned
patients). There occurs a level of pain reduction that is beyond that which
would be expected with typical oral NSAID use. While the diclofenac patch
has been approved for use in low back strain it has not been investigated
for complex clinical low back pain conditions as presented.
Results: The clinical case presentations demonstrate the beneﬁt of ap-
propriately titrated long acting opiates. Also seen is an additional degree
of analgesic relief with the diclofenac patch 1.3%. Once pain has been
adequately modulated only then can sleep augmentation be successfully
introduced with tizanidine capsules to treat co existing FIBRO. The clinical
result is a much more optimally controlled level of pain and a higher level
of function.
Conclusions: Just as in the treatment of hypertension and cancer,
typically the treatment of low back pain associated with OA, DDD, M-SP
and FIBRO may require the use of multiple medications. When traditional
treatment methods fail to arrive at an acceptable clinical result then
appropriately titrated opiates can be effective. Non narcotic diclofenac
patches offer additional clinical beneﬁt. Once pain modulation is ade-
quately accomplished, tizanidine capsules can be used to effectively treat
coexisting ﬁbromyalgia.
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551 TREATMENT OF CARTILAGE DEFECTS IN THE KNEE
USING ALGINATE BEADS CONTAINING HUMAN MATURE
ALLOGENIC CHONDROCYTES
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Purpose: To determine whether the implantation of alginate beads con-
taining human mature allogenic chondrocytes in symptomatic cartilage
defects of the knee results in structural regeneration of the joint surface
and improves clinical outcome.
Methods: A biodegradable, alginate-based biocompatible scaffold con-
taining human mature allogenic chondrocytes was used for the treatment
of chondral and osteochondral lesions in the knee. Twenty-one patients
were clinically prospectively evaluated with use of the Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC) and a Visual
Analogue Scale (VAS) for pain preoperatively and at 3, 6, 9 and 12 months
of follow-up. Of the 21 patients, 13 had consented to the taking of a biopsy
for investigative purposes from the area of implantation at 12 months of
follow-up, allowing histological assessment of the repair tissue.
Results: A statistically signiﬁcant clinical improvement became apparent
after 6 months and patients continued to improve during the 12 months
of follow-up. Adverse reactions to the alginate/ﬁbrin matrix seeded with
